Shares of 10x Genomics, Inc. (NASDAQ:TXG – Get Free Report) have received a consensus rating of “Hold” from the seventeen analysts that are currently covering the company, Ratings reports. One ...
Hosted on MSN1mon
10x Genomics (NASDAQ:TXG) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses ExpectationsB iotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million. On the other hand, the company’s full-year revenue guidance of $620 ...
Genomics (TXG) provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, in ...
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...
Genomics (NASDAQ:TXG – Get Free Report)‘s stock had its “sell (e+)” rating restated by equities researchers at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports. A number of ...
Whitaker, Chief Legal Officer of 10x Genomics. "We are pleased with this resolution on ATAC as we continue to defend the asserted Brenner patents on appeal." The company's litigation against Parse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback